217 related articles for article (PubMed ID: 16804806)
41. Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: effectiveness for depression and anger symptoms.
Mercer D; Douglass AB; Links PS
J Pers Disord; 2009 Apr; 23(2):156-74. PubMed ID: 19379093
[TBL] [Abstract][Full Text] [Related]
42. Prescribing patterns of neuroactive drugs in 98 schizophrenic patients.
Heresco-Levy U; Greenberg D; Wittman L; Dasberg H; Lerer B
Isr J Psychiatry Relat Sci; 1989; 26(3):157-63. PubMed ID: 2575085
[TBL] [Abstract][Full Text] [Related]
43. Effects of antipsychotic polypharmacy on side-effects and concurrent use of medications in schizophrenic outpatients.
Hashimoto Y; Uno J; Miwa T; Kurihara M; Tanifuji H; Tensho M
Psychiatry Clin Neurosci; 2012 Aug; 66(5):405-10. PubMed ID: 22834658
[TBL] [Abstract][Full Text] [Related]
44. Antipsychotics: to combine or not to combine?
Sagud M; Vuksan-Ćusa B; Zivković M; Vlatković S; Kramarić M; Bradaš Z; Mihaljević-Peleš A
Psychiatr Danub; 2013 Sep; 25(3):306-10. PubMed ID: 24048402
[TBL] [Abstract][Full Text] [Related]
45. Description of long-term polypharmacy among schizophrenia outpatients.
Suokas JT; Suvisaari JM; Haukka J; Korhonen P; Tiihonen J
Soc Psychiatry Psychiatr Epidemiol; 2013 Apr; 48(4):631-8. PubMed ID: 23007295
[TBL] [Abstract][Full Text] [Related]
46. Polypharmacy in the treatment of schizophrenic patients in three University Centers in the Federation of Bosnia and Herzegovina (F/BH).
Loga-Zec S; Loga S
Psychiatr Danub; 2011 Mar; 23(1):60-3. PubMed ID: 21448098
[TBL] [Abstract][Full Text] [Related]
47. Pharmacological approaches to the management of schizophrenia: 10 years on.
Castle D; Keks N; Newton R; Schweitzer I; Copolov D; Paoletti N; Burrows G; Tiller J
Australas Psychiatry; 2013 Aug; 21(4):329-34. PubMed ID: 23616381
[TBL] [Abstract][Full Text] [Related]
48. Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations.
Lähteenvuo M; Tiihonen J
Drugs; 2021 Jul; 81(11):1273-1284. PubMed ID: 34196945
[TBL] [Abstract][Full Text] [Related]
49. Pharmacotherapy of patients with schizophrenia and substance abuse.
Wobrock T; Soyka M
Expert Opin Pharmacother; 2009 Feb; 10(3):353-67. PubMed ID: 19191675
[TBL] [Abstract][Full Text] [Related]
50. Polypharmacy in schizophrenia.
Baandrup L
Basic Clin Pharmacol Toxicol; 2020 Mar; 126(3):183-192. PubMed ID: 31908124
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of the individual safe correction of antipsychotic agent polypharmacy in Japanese patients with chronic schizophrenia: validation of safe corrections for antipsychotic polypharmacy and the high-dose method.
Yamanouchi Y; Sukegawa T; Inagaki A; Inada T; Yoshio T; Yoshimura R; Iwata N
Int J Neuropsychopharmacol; 2014 Dec; 18(5):. PubMed ID: 25522380
[TBL] [Abstract][Full Text] [Related]
52. Antipsychotic polypharmacy: do benefits justify the risks?
Tapp AM; Wood AE; Kilzieh N; Kennedy A; Raskind MA
Ann Pharmacother; 2005 Oct; 39(10):1759-60. PubMed ID: 16144885
[No Abstract] [Full Text] [Related]
53. The role of psychopharmacotherapy in improving the long-term outcome of schizophrenia.
Alam DA; Janicak PG
Essent Psychopharmacol; 2005; 6(3):127-40. PubMed ID: 15869020
[TBL] [Abstract][Full Text] [Related]
54. Adjunctive versus monotherapeutic treatment for schizophrenia: addressing antipsychotic side effects.
Hazra M; Mamo DC; Remington G
Am J Psychiatry; 2008 Mar; 165(3):396-7; author reply 397-8. PubMed ID: 18316434
[No Abstract] [Full Text] [Related]
55. [Polypharmacy in schizophrenia].
Zink M; Englisch S; Meyer-Lindenberg A
Nervenarzt; 2011 Jul; 82(7):853-8. PubMed ID: 21165589
[TBL] [Abstract][Full Text] [Related]
56. Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia.
Suzuki T; Uchida H; Tanaka KF; Nomura K; Takano H; Tanabe A; Watanabe K; Yagi G; Kashima H
Int J Neuropsychopharmacol; 2004 Jun; 7(2):133-42. PubMed ID: 14741059
[TBL] [Abstract][Full Text] [Related]
57. Should patients with schizophrenia receive antidepressants?
Terevnikov V; Stenberg JH; Joffe G
Duodecim; 2017; 133(5):465-71. PubMed ID: 29205993
[TBL] [Abstract][Full Text] [Related]
58. The schizophrenia prodrome: a developmentally informed review and update for psychopharmacologic treatment.
Thomas LE; Woods SW
Child Adolesc Psychiatr Clin N Am; 2006 Jan; 15(1):109-33. PubMed ID: 16321727
[TBL] [Abstract][Full Text] [Related]
59. [Recent advances in clinical psychopharmacology].
Mori A
Yakubutsu Seishin Kodo; 1984 Nov; 4(3):201-12. PubMed ID: 6152505
[TBL] [Abstract][Full Text] [Related]
60. [Changes in the clinical picture and course of psychoses as a result of massive psychopharmacotherapy and their role in improving treatment services].
Avrutskiĭ GIa
Zh Nevropatol Psikhiatr Im S S Korsakova; 1979; 79(9):1387-94. PubMed ID: 40371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
